Merck (MRK) company logo

Merck Stock Calculator

Estimate your Merck ($MRK) stock returns over time

Merck Investment Calculator

Calculate potential returns on your Merck stock investment using historical performance data.

Investment Parameters

Enter an amount between $1 and $1 billion
Enter a period between 1 and 50 years

Investment Projection Results

Initial Investment: —
Hold Period: —
Expected Annual Return: —
Future Value: —
Total Return: —

What This Means For You

Enter your investment details above to see personalized insights.

Investment Growth Over Time

Frequently Asked Questions

This calculator allows you to project returns on Merck stock over time. Input your initial investment, holding period, and return rate. Experiment with different values to see how compounding impacts your potential growth.

Merck has demonstrated varying returns across different time periods. The 5Y return of 15.58% provides the most comprehensive historical view. Our weighted average annual return of 1.96% gives more weight to longer-term performance. However, past performance doesn't guarantee future results, and returns can vary significantly year to year.

Several factors can influence Merck's stock performance:

  • Company earnings and revenue growth
  • Market conditions and economic trends
  • Industry-specific developments
  • Company announcements and news
  • Overall market sentiment

The calculator provides two key metrics:

Future Value

The projected value of your investment at the end of your holding period

Total Return

The absolute dollar amount gained or lost, plus the percentage return on your investment

Remember that these are projections based on your inputs and historical data. Actual returns may differ significantly.

Explore More Stock Calculators

Popular Stock Calculators

Compare returns across different stocks and sectors

Browse All Stocks

Healthcare Sector

Other stocks in the Healthcare sector

View Sector Stocks

Historical Returns

1Y Return
-36.73%
2Y Return
-26.09%
3Y Return
-9.69%
4Y Return
20.31%
5Y Return
15.58%
YTD Return
-21.54%
Last Updated: 2025-06-04 14:21:17

Merck Information

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Business Classification

Sector Healthcare
Industry Drug Manufacturers - General

Location

Rahway, NJ, United States

Company Size

73,000 employees

Resources & Data Sources

Stock data powered by Yahoo Finance API
Company logos provided by Parqet Logo API
Market data and calculations are for informational purposes only and should not be considered as financial advice.